跳到正文
原文
STAT 主站· Katherine MacPhail·· 28 天前AI 评分28

Pathos 人工智能制药公司获 2.37 亿美元融资估值达 30 亿美元

STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion

AI 导读

Pathos 是一家人工智能驱动的药物开发公司,宣布获得 2.37 亿美元的 E 轮融资,估值达到约 30 亿美元。该公司正从肿瘤学扩展到神经疾病领域,与 BMS 合作开发阿尔茨海默病治疗药物。Pathos 的 Foundry 模型通过分析临床数据、基因组学和生物样本数据,指导药物开发决策。

正文

Pathos, an artificial intelligence-driven drug development company, announced on Friday it is raising $237 million in a Series E fundraising round led by Bristol Myers Squibb. The deal brings Pathos’ valuation to approximately $3 billion.

Pathos is also expanding from oncology to neurological conditions with new datasets from Tempus AI and a partnership with BMS that will first focus on Alzheimer’s treatments. 

Most drugs that enter clinical trials never reach patients, but Pathos’ pitch is that AI can improve the odds. Its proprietary model, Foundry, operates thousands of agents that calculate the probability of success for its clinical assets. The agents analyze clinical data, genomics, biological specimen data, and competition from other developers. This information guides Pathos’s decision-making on which drugs to pursue, what populations to test them in, and how to design the clinical trials. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com